- $281.82m
- -$10.72m
- $0.93m
- 58
- 16
- 11
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.88 | ||
| Price to Tang. Book | 0.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 277.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.8% | ||
| Return on Equity | -34.97% | ||
| Operating Margin | -9702.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.93 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Directors
- Todd Simpson NEC (60)
- Jonathan Drachman PRE (59)
- Robert Ho CFO (45)
- Carl Walkey SVP (36)
- Bill Arthur VPR
- Priti Patel OTH
- Martin Babler IND (56)
- M. Cantey Boyd IND (41)
- Erin Lavelle IND (43)
- Sarah Noonberg IND
- Lewis Williams IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- May 25th, 2007
- Public Since
- March 7th, 2014
- No. of Shareholders
- 16
- No. of Employees
- 107
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 14,262,066
- Address
- 535 W 24Th Street, 5Th Floor, NEW YORK, 10011
- Web
- https://www.neurogene.com/
- Phone
- +1 2067322133
- Auditors
- Ernst & Young LLP
Upcoming Events for NGNE
Neurogene Inc at Goldman Sachs Global Healthcare Conference
Neurogene Inc Annual Shareholders Meeting
Neurogene Inc Annual Shareholders Meeting
Q2 2025 Neurogene Inc Earnings Release
Q3 2025 Neurogene Inc Earnings Release
Q3 2025 Neurogene Inc Earnings Release
Similar to NGNE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Neurogene share price?
As of Today at 22:14 UTC, shares in Neurogene are trading at $17.99. This share price information is delayed by 15 minutes.
How has the Neurogene share price performed this year?
Shares in Neurogene last closed at $17.99 and the price had moved by -46.65% over the past 365 days. In terms of relative price strength the Neurogene share price has underperformed the S&P500 Index by -52.51% over the past year.
What are the analyst and broker recommendations for Neurogene?
The overall consensus recommendation for Neurogene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neurogene dividend yield?
Neurogene does not currently pay a dividend.
Does Neurogene pay a dividend?
Neurogene does not currently pay a dividend.
When does Neurogene next pay dividends?
Neurogene does not currently pay a dividend.
How do I buy Neurogene shares?
To buy shares in Neurogene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neurogene?
As of the previous close price of $17.99, shares in Neurogene had a market capitalisation of $256.57m.
Where are Neurogene shares listed?
Here are the trading details for Neurogene:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NGNE
What kind of share is Neurogene?
Based on an overall assessment of its quality, value and momentum Neurogene is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neurogene share price forecast for 2025?
The analyst consensus target price for shares in Neurogene is $40.60. That is 125.68% above the last closing price of $17.99.
Analysts covering Neurogene currently have a consensus Earnings Per Share (EPS) forecast of -$4.72 for the next financial year.
Find out moreWhat is the trend in the Neurogene share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurogene. Over the past six months, its share price has underperformed the S&P500 Index by -48.44%.
As of the last closing price of $17.99, shares in Neurogene were trading -34.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neurogene PE Ratio?
The Neurogene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neurogene?
Neurogene's management team is headed by:
- Todd Simpson - NEC
- Jonathan Drachman - PRE
- Robert Ho - CFO
- Carl Walkey - SVP
- Bill Arthur - VPR
- Priti Patel - OTH
- Martin Babler - IND
- M. Cantey Boyd - IND
- Erin Lavelle - IND
- Sarah Noonberg - IND
- Lewis Williams - IND